CG Oncology, Inc. Common stock (CGON)

USD 28.45

(-2.8%)

Market Cap (In USD)

2.16 Billion

Revenue (In USD)

204 Thousand

Net Income (In USD)

-48.6 Million

Avg. Volume

745.48 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
25.77-50.23
PE
-
EPS
-
Beta Value
0.0
ISIN
US1569441009
CUSIP
-
CIK
1991792
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Arthur Kuan
Employee Count
-
Website
-
Ipo Date
Details
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.